Queensland Delegation Strengthens India-Australia Life Sciences Collaboration at BioAsia 2026

Queensland Delegation Strengthens India-Australia Life Sciences Collaboration at BioAsia 2026

India, Feb 19th: Trade and Investment Queensland (TIQ), Queensland Government’s global business agency, in partnership with Australian Trade and Investment Commission (Austrade), concluded a successful mission at BioAsia 2026, Asia’s premier life sciences and biotechnology forum, organized annually by the Government of Telangana, India.

Aligned with the Queensland Government’s “QueensLand of Opportunity” vision, the delegation to India showcased the state’s capabilities in biotechnology drug discovery, clinical trials, and digital health. Strategic engagements across Hyderabad and Bengaluru enabled direct connections with India’s rapidly expanding innovation ecosystem, paving the way for deeper research, commercial, and investment partnerships.

India presents a high-growth market opportunity for Australian organisations across vaccine research and development, cell and gene therapy innovation, clinical trials, and MedTech, enabling deeper scientific collaboration and accelerated translational outcomes. Consequently, Australia remains a highly trusted clinical trial site for Indian biopharma and medical technology companies to conduct clinical trials with fast trial start-up options and high data acceptability worldwide, especially for early-phase studies and trials.

The mission involved participation of the delegates at the BioAsia conference and exhibition, and a dedicated Clinical Trials Roundtable, along with B2B meetings to facilitate commercial partnerships and enhance mutual market awareness.

Commenting on the visit, Abhinav Bhatia, Senior Trade & Investment Commissioner – South Asia, Trade and Investment Queensland, said, “India is the ‘Pharmacy of the World,’ but the next era of medicine is about moving from volume to value. At BioAsia 2026, we’ve demonstrated that Queensland is the ‘Strategic Lab’ for India’s ‘Global Factory.’ By combining our world-class research and 43.5% R&D tax incentives with India‘s manufacturing scale, we aren’t just cutting costs—we are cutting the time it takes to save lives.” 

Reflecting on the depth of engagement at BioAsia 2026, Ms Mary Overington, Trade and Investment Commissioner, Australian Trade and Investment Commission said, “This visit demonstrated the complementary strengths of Australia‘s research-led innovation and India‘s scale in clinical research and manufacturing. Through focused roundtables and stakeholder meetings, the Australian delegation explored practical collaboration opportunities across clinical trials, biotech R&D and life sciences manufacturing. The strong industry response signals clear momentum towards deeper partnerships and commercial engagement between Australia and India in the health and life sciences sector.”